Supporting Publications

SERD

• Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment

  Patel, H. K., Bihani, T. (2018) Pharmacology & Therapeutics

• Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with Fulvestrant: results from NEWEST, a randomized Phase II study

  Kuter, I. .et al. (2012) Breast Cancer Research and Treatment

• Pharmacokinetic and pharmacodynamic analysis of Fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

  Wardell, S. E. .et al. (2019)

• Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial

  Di Leo A, et al. (2014) J Natl Cancer Inst.

• Buparlisib plus Fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

  Leo, A. D. et al. (2018) The Lancet Oncology

WEE1

• Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy

  Fang, Y. et al. (2019) Cancer Cell

• Dose Escalation Trial of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Gemcitabine and Radiation for Patients with Locally Advanced Pancreatic Cancer

  Cuneo, K. C. et al. (2019) J of Clinical Oncology

• Phase II Study of WEE1 Inhibitor AZD1775 plus Carboplatin in Patients with TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

  Leijen, S. et al. (2016) J of Clinical Oncology

BCL-2

• A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer

  Lok, S. W. et al. (2019) Cancer Discovery

EGFR

• AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer: NEJM

  Jänne, P. A. et al. (2015) New England J of Medicine